WO2007026474A1 - 栄養組成物 - Google Patents
栄養組成物 Download PDFInfo
- Publication number
- WO2007026474A1 WO2007026474A1 PCT/JP2006/314192 JP2006314192W WO2007026474A1 WO 2007026474 A1 WO2007026474 A1 WO 2007026474A1 JP 2006314192 W JP2006314192 W JP 2006314192W WO 2007026474 A1 WO2007026474 A1 WO 2007026474A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nutritional composition
- protein
- composition according
- mass
- viscosity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0241—Containing particulates characterized by their shape and/or structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/062—Oil-in-water emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/30—Characterized by the absence of a particular group of ingredients
- A61K2800/33—Free of surfactant
Definitions
- the present invention relates to a novel nutritional composition, more specifically, a liquid or semi-solid nutritional composition containing a specific amount of protein, having a specific volume-based median diameter, and 2
- the present invention relates to a nutritional composition containing water-insoluble particles mainly composed of a protein insolubilized with a cation.
- Nutrients necessary for carrying out life support activities are carbohydrates, proteins, lipids, inorganic salts
- Patent Document 1 a high-protein nutritive thread and an adult product are known.
- the main focus is on maintaining a high protein and flavor.
- the amount of nutrients especially minerals such as sodium, potassium, calcium, and magnesium, the emphasis is on the stability of emulsion stability.
- gastrostomy enteral tube feeding method is becoming widespread as an aspect of tube feeding.
- This gastrostomy 'intestinal tube feeding method is a nutritional method through a tube in which an external fistula (fistula) is constructed and placed in the esophagus, stomach, and jejunum (mostly the stomach).
- This is a method of continuous or intermittent administration of a medicine, which can supply nutrients directly to the stomach and intestines. Therefore, it is said that water and nutrients can be ingested through the digestive tract as well as healthy people, and the quality of life (hereinafter referred to as QOL) of patients can be improved.
- QOL quality of life
- the nutritional composition when the nutritional composition is introduced into the stomach or intestine via a tube or the like, it can be easily administered if the nutritional composition has a high viscosity and strong adhesion. Disappear.
- a nutritional composition that is a high protein and can be easily introduced into a patient without impairing the taste and flavor by using various administration methods as an emulsion in water as a dispersion medium. It was very difficult to prepare by a method of uniformly dispersing.
- An object of the present invention is a nutritional composition of high protein, which contains necessary nutrients other than protein without excess and deficiency, and can be easily and easily introduced into a patient by various administration methods. It is an object of the present invention to provide a nutritional composition that is excellent in sterilization heat resistance and storage stability, and that can be mass-produced at low cost without requiring a complicated manufacturing apparatus process. In particular, the present invention is to provide a nutritional composition having rheological properties that is preferable for oral intake and tube force administration even when the amount of protein or mineral is increased.
- a high-calorie nutritional composition exceeding 1.5 kcal / ml, sufficient protein and minerals that were insufficient in the conventional compounding amount when assuming an energy intake of 1, OOOkcal / day are sufficient. It is intended to provide a nutritional composition that is contained in an amount and that is free from problems in production, distribution, and use.
- the present invention is a liquid or semi-solid nutritional composition containing at least carbohydrates, lipids, proteins and minerals, wherein the volume-based median diameter (d50) of particles in the nutritional composition is 5 ⁇ : LOO / zm, wherein the nutritional composition contains water-insoluble particles whose main component is a protein insoluble in a divalent cation. Concerning things.
- the average particle size of the particles in the nutritional composition is preferably 400 m or less.
- the volume-based median diameter (d50) of water-insoluble particles in the nutritional composition is 10 to: L00 m is preferred.
- the present invention is a liquid or semi-solid nutritional composition containing at least carbohydrates, lipids, proteins and minerals, wherein the nutritional composition is insolubilized with a divalent cation.
- Nutrients that contain water-insoluble particles mainly composed of protein, and whose protein mass is 1.5 to 3 gZ mmol, based on the total number of moles of divalent ions forming the water-insoluble particles. Relates to the composition.
- the nutritional composition preferably has a viscosity of 400-7, OOOmPa's after being held at 25 ° C. More preferably, the nutritional composition has a viscosity power of 1,000 to 7, OOOmPa's after being held at 25 ° C.
- the nutrient composition has a viscosity of 1S 200 to 3, OOOmPa's after being held at 25 ° C, then heated to 37 ° C and held for 30 minutes.
- the nutritive fiber composition has a calorie of 1.5 to 2.2 kcalZg, a protein of 7 to 14% by mass, a fat of 3 to 7% by mass, and a carbohydrate of 20 to 35% by mass.
- the nutritional composition preferably contains 0.05 to 2.0% by mass of free glutamic acid.
- the nutritional composition may promote gastric emptying from the stomach.
- the nutritional composition can be for enteral use.
- the nutritional composition can be for the treatment of gastrointestinal tract function.
- the nutritional composition can be for the treatment of undernutrition.
- the nutritional composition can be used for the prevention and treatment of reflux esophagitis.
- the nutritional composition may be for the prevention / treatment of aspiration pneumonia.
- the nutritional composition of the present invention contains the necessary nutrients without excess or deficiency, is a high protein, can be easily and easily introduced into a patient by various administration methods, and also has a bactericidal heat resistance and storage stability. It is a nutritional composition that is excellent in performance and does not require complicated manufacturing equipment and processes and can be mass-produced at low cost.
- FIG. 1 is a schematic diagram for explaining a method of a gastroesophageal reflux test performed in Test Example 3.
- FIG. 2 is a graph showing the relationship between the viscosity of the composition and the effect of preventing gastroesophageal reflux (Test Example 3).
- FIG. 3 is a graph showing the relationship between the viscosity of the composition and the extrudability (Test Example 4).
- FIG. 4 is a graph showing the amount of liquid remaining in a tube-type gastrostomy catheter after liquid washing of each composition (Test Example 6).
- FIG. 5 is a graph showing the amount of liquid remaining in a button-type gastrostomy catheter after liquid washing of each composition (Test Example 6).
- the nutritional composition of the present invention is not limited to micronizing or homogenizing a conventional protein, and is preferable rheology without increasing viscosity or adhesion by making a certain particle size range even in a non-uniform state.
- the container can be easily and continuously filled, it can be easily and easily introduced into patients by various administration methods, and it has excellent sterilization heat resistance and storage stability. The state is maintained.
- various protein raw materials may be present in the preparation solution in the form of particles insoluble in divalent cations.
- the present invention is a liquid or semi-solid nutritional composition containing at least carbohydrates, lipids, proteins and minerals, and a volume-based median diameter of particles in the nutritional composition (d50) Is 5 ⁇ : LOO / zm, and the nutritional composition contains water-insoluble particles mainly composed of a protein insoluble with divalent cations. It provides things.
- the present invention also includes a liquid or semi-solid nutritional composition containing at least carbohydrates, lipids, proteins and minerals, wherein the protein insolubilized with a divalent cation is contained in the nutritional composition.
- a nutritional composition containing water-insoluble particles as a main component and having a protein mass of 1.5 to 3 gZ mmol with respect to the total number of moles of divalent ions forming the water-insoluble particles. It is to provide. [0019]
- the nutritional composition of the present invention will be described in more detail.
- the protein content in the nutritional composition of the present invention is preferably 7 to 14% by mass.
- a high-calorie and high-protein nutritional thread and product can be obtained. That is, even when the calorific value is 1.5 to 2.2 kcalZg, it is possible to obtain 40 to 50 gZ days, which is the necessary protein mass of an elderly person 70 years or older, with only the nutritional composition.
- Proteins include milk proteins such as casein and its salt, whey, soy protein, wheat protein, corn protein, fish protein, egg protein, etc., and raw materials obtained by processing these into powder, granules, flakes or pellets. Including. In the present invention, at least one of these intermediate forces is used.
- casein or a salt thereof it is preferable to contain at least 2 to 8% by mass of casein or a salt thereof because the particle size of water-insoluble particles can be easily controlled.
- a hydrolyzate or amino acid of the protein raw material may be added as a material for supplementing the protein.
- these proteins and materials as a protein supply source do not need to be completely insoluble, and insoluble substances and dissolved substances can be present in various ratios depending on the formulation composition.
- the free glutamic acid content is 0.05 to 2.0 mass% in the nutritional composition, because the protein source used in the present invention, that is, the protein raw material, the peptide raw material, and the amino acid raw material power is also derived.
- Carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as sucrose and maltose, oligosaccharides, dextrin, starch, sugar alcohol, thickening polysaccharides, water-soluble dietary fiber and insoluble food fiber. At least one type is selected and used.
- the content of the carbohydrate in the nutritional composition of the present invention is preferably 20 to 35% by mass! /.
- Lipids include canola oil, soybean oil, corn oil, sesame oil, safflower oil, palm oil, other vegetable oils, fish oil, butter, pig oil and other animal oils, and emulsifiers and medium chains that contain fatty acids in the structure. At least one type selected from functional oils and fats such as fatty acid triglycerides is used.
- the lipid content in the nutritional composition of the present invention is preferably 3-7% by mass.
- Examples of minerals include minerals essential as nutritional components, such as sodium, potassium, calcium, magnesium, phosphorus, chlorine, iron, zinc, copper, and manganese.
- Divalent cations include nutrients such as calcium, magnesium, iron, zinc, copper, and man Ions such as cancer can be mentioned, and at least one selected from these inorganic salts or organic acid salts can be used as a raw material.
- the protein mass is 1.5 to 3 gZmmol, preferably 2 to 3 gZmmol, with respect to the total number of moles of divalent ions forming water-insoluble particles.
- the preparation solution into which the protein raw material is charged should have either a gallium ion or a magnesium ion as a divalent cation, but more preferably both calcium ion and magnesium ion.
- the water-insoluble particles should be prepared so that the protein mass is 1.5 to 3 gZmmol with respect to the total number of moles of calcium and magnesium.
- the amount of polyvalent anions such as sulfate ion, carbonate ion, phosphate ion and organic acid ion paired with sodium ion and potassium ion is too much compared to the amount of divalent cation.
- the divalent cation and the polyvalent anion form an insoluble salt and precipitate, so that the aggregation of the protein is difficult to proceed and the white precipitate tends to be easily formed during storage. Therefore, the amount of polyvalent anions is preferably as small as possible from this point of view, but is preferably determined in view of adjustment of optimum pH, good flavor, viscosity, and nutritional component composition.
- water-insoluble particles mainly composed of insoluble protein refers to particles that are easily precipitated by centrifuging the composition at, for example, 3, OOOrpm. It is preferable that the precipitated particles have a volume-based median diameter (d50) of 10 to: LOO m, particularly preferably 10 to 30 m. Above 100 m, there is a tendency for the feeling of roughness to increase when taken orally. If it is less than 10 / z m, the viscosity tends to be high and the stickiness tends to be strong, and the force of pushing out the nutritional composition tends to be too high when administered by tube.
- This insolubilized particle differs from, for example, the casein calcium dispersed state (casein micelle) present in milk in that it does not precipitate easily even when the casein calcium is centrifuged.
- the particle diameter was measured with a laser scattering particle size distribution measuring apparatus.
- a PIDS (Polarized Differential Scattering) assembly is used and the refractive index is measured as a liquid (suspended).
- Liquid part 1. 32, Sample: Real part 1.45, Imaginary part 0.
- Powerful insoluble protein particles are produced by reacting a protein with a divalent cation and possibly a divalent cation together with a divalent cation, thereby changing the protein's three-dimensional structure or charged state.
- the divalent cation may be mixed with the protein as an insoluble or poorly soluble salt such as citrate, sulfate, phosphate, carbonate, etc., but it may be easily mixed with lactate, hydrochloride, etc. It is preferable to mix with the protein as a solution in the form of a soluble salt. By introducing the solution as a solution, it is possible to prevent the protein dispersed and dispersed from reacting rapidly to form coarse particles. In addition, it is preferable to gradually add and mix the divalent cation and the protein. It is preferable to mix the protein solution while stirring at high speed.
- high-speed stirring means stirring at 5000 rpm or less.
- the order of preparation of the monovalent cation, divalent cation and protein is preferably monovalent cation, protein and divalent cation.
- a large amount of insoluble salt tends to be formed depending on the molar ratio and concentration of polyvalent anion and divalent cation in the mixed solution.
- the water-insoluble particles are mainly composed of proteins
- lipids and carbohydrates may form a complex with the protein.
- the insolubilized components of lipids, proteins and divalent cation salts may be present alone or as a complex.
- the volume-based median diameter (d50) of the nutritional composition of the present invention is 5 to: LOO / z m, preferably 20 to 50 m.
- the volume-based median diameter (d50) of the water-insoluble particles containing the insolubilized protein as the main component is preferably 10 to: LOO ⁇ m.
- the volume-based median diameter (d50) of all these particles is 5 to 100 ⁇ m.
- the viscosity of the preparation solution decreases and a nutritional composition having an arbitrary particle size distribution can be prepared, but the volume-based median diameter (d50 ), A decrease in viscosity is observed, but the nutritional composition does not reach the desired fluidity in the tube in terms of both viscosity and adhesion. Also, volume-based median diameter exceeding 100 m ( In the nutritional composition having d50), the homogeneity in the production process of many active ingredients including proteins cannot be ensured, and a taste that is very rough when taken orally is not preferred for swallowing. Furthermore, there is a risk that tube clogging will occur frequently during tube administration.
- the average particle size of the particles in the nutritional composition of the present invention is preferably 400 ⁇ m or less, more preferably 5 to 200 / ⁇ ⁇ .
- the volume-based median diameter (d50) does not exceed 100 m even if particles containing more than 100 m other than insoluble particles are contained in the nutritional composition. If so, it can be used without any problem in flavor and tube fluidity.
- the insolubilized particles are easily separated simply by leaving the nutritional composition, the commercial value may be impaired, and aged pneumonia may occur in elderly people with reduced swallowing / chewing ability. Even if it is separated, it is preferable that it is redispersed by shaking and not easily separated again, so that the viscosity of the nutritional composition is preferably somewhat high. On the other hand, if the viscosity is too high, the residual amount in the tube that is difficult to take by oral tube will also increase. Therefore, the viscosity of the nutritional composition should be 400 mPa's or more, especially 1, OOOmPa's or more at 25 ° C, and it should be more than 7, OOOmPa's, especially 3, OOOmPa's or less.
- OOOmPa's can be taken by oral tube and immediately reduce the residual amount in the tube, and the tube can be easily cleaned, and reflux esophagitis and aspiration pneumonia Can be prevented.
- the viscosity mentioned here is a value measured assuming a fluid state when ingested by oral tube, and the form before ingestion may not be liquid. For example, before use, it may be in a non-flowing state such as purine jelly, and may be in a semi-solid form that exhibits fluidity when the tissue is collapsed by external force.
- the viscosity is a value measured with a rotary viscometer at No. 3 port, 1 ter, 12 rpm, 25 ° C (the same applies hereinafter).
- the adjustment of the viscosity can also be achieved by using a thickener or a gelling agent.
- the viscosity modifier include agar, carrageenan, fercellan, alginate, gelatin, pectin, mannan, dielan gum, cassia gum, locust bean gum, gum arabic, tara gum, guar gum, xanthan gum and starch.
- agar as a gelling agent, shearing It is preferable to impart to the nutritional composition of the present invention the property of plastic flow that begins to flow when the stress exceeds the yield value.
- a preferred nutritional composition for enteral tube feeding can be provided. More specifically, it prevents the occurrence of reflux gastroesophagitis, reduces the frequency of diarrhea, and prevents the leakage of nutrients in the abdominal wall implantation force used in gastrostomy Therefore, it is preferable to add a gelling agent to prepare an appropriate gel strength.
- the nutritional composition of the present invention preferably has a viscosity of 200-3, OOOmPa's after being held at 25 ° C, heated to 37 ° C and further held for 30 minutes.
- a viscosity of 200-3, OOOmPa's after being held at 25 ° C, heated to 37 ° C and further held for 30 minutes.
- the nutritional composition of the present invention may contain vitamins and dietary fiber that are essential as nutrients in addition to the above-mentioned raw materials.
- Catechin, carnitine, coenzyme Q, GABA, ⁇ -lipoic acid Functional food materials represented by the above may be contained.
- In order to improve the flavor, seasonings, colorants, sweeteners, fragrances, and ⁇ ⁇ adjusters may be used as food-derived raw materials and extracts, and food additives.
- ⁇ of the nutritional composition varies depending on the type of raw material used and the intake form. In general, most proteins are denatured due to a decrease in ⁇ , causing aggregation and precipitation, and becoming nearly insoluble.
- the preferred water-insoluble particle state in the present invention that is, the volume-based median diameter (d50) is set to 10 to: LOO m, or the viscosity is adjusted so that the particles are difficult to separate during storage. Therefore, the pH of the nutritional composition should be 4.8 to 7.2, especially 5.6 to 6.6.
- the viscosity of the nutritional composition is significantly reduced by insolubilizing the protein. Therefore, the effect is exhibited especially in a high calorie composition.
- a composition with a calorific value of 1.5 to 2.2 kcalZg and an energy ratio of 20 to 25% of protein an ideal formulation can be achieved.
- the protein content at that time is preferably 7 to 14% by mass. If the energy ratio of lipid is 20-30%, the lipid content is 3-7% by mass, which is a preferable nutritional composition.
- a carbohydrate is added to water heated to 60 ° C or higher, and then a salt containing a monovalent cation is mixed.
- a salt containing a monovalent cation is mixed.
- fats and oils and an emulsifier as necessary are mixed, and the protein is further mixed and stirred to disperse and dissolve the protein.
- This is mixed with a salt containing a divalent cation and stirred to insolubilize the protein.
- mix vitamins, dietary fiber, and fragrance as necessary stir, and then add water to make up the volume.
- an emulsification operation using a generally used high-pressure homogenizer, ultrasonic emulsifier, colloid mill, high-speed homomixer, or the like is not necessarily required.
- oil droplets are dispersed as fine emulsions in water like conventional liquid liquid foods, and are therefore contained or interacted with insoluble protein particles that are present in an aggregated and aggregated state.
- t derived from a new manufacturing process.
- the operation with the high-speed homomixer refers to stirring at 5000 rpm or higher.
- the nutritional composition of the present invention was prepared based on a production method selected to avoid significant emulsification breakage promotion by being treated at a high temperature for a long time.
- the nutritional composition of the present invention can be sterilized using a retort system that is treated at a high temperature for a long time. This is because, as described above, it is based on a novel production method based on insolubilizing proteins, and it is not always necessary to suppress the destruction of the preparation due to the aggregation and coalescence of fine engineered marguillon.
- the nutritional composition of the present invention can be filled in various forms of containers depending on the application, and can be provided to the user after the retort sterilization treatment.
- the nutritional composition of the present invention is suitable for power that can be used for oral and tube feeding, particularly for enteral use.
- the nutritional composition of the present invention is adjusted to an appropriate viscosity and contains the necessary nutritional sources in a well-balanced manner.
- free glutamic acid is contained in the nutritional composition in an amount of 0.05 to 2% by mass, so that the stomach contents are promoted and a more preferable nutritional composition is obtained.
- the increase in viscosity due to the dissolution of the protein at a high concentration can be remarkably suppressed by insolubilizing the protein.
- the presence state of lipids is different from existing emulsion such as liquid liquid food, (1) advantages in production, (2) advantages in ingestion administration, and (3) advantages in nutritional composition can be considered. Each is described below.
- An advantage in the nutritional composition is that high concentrations of proteins and minerals, particularly sodium, strength rhodium, calcium, and magnesium can be blended. Proteins are present in an insolubilized state, and lipids are dispersed in a form different from the conventional liquid liquid food emulsion, so it is almost necessary to take into account the demulsification caused by the listed minerals. No. As described above, the nutritional composition of the present invention can be prepared into a low-weight / high-calorie preparation, and can easily carry out nutritional supplementation of proteins, minerals, and the like, especially for elderly people whose stomach volume is reduced. .
- the preparation method when 4000g is charged is described below.
- the amount of each raw material is as shown in Tables 1-3.
- 1420g of prepared water was weighed in a 5L stainless steel bucket and heated to 70-80 ° C in a hot water bath.
- TK Robotics registered trademark, manufactured by Tokushu Kika Kogyo Co., Ltd.
- 3 OOOrp m high-speed stirring conditions dextrin, granulated sugar, ferrous sodium citrate, sodium phosphate, potassium phosphate , Tripotassium citrate and sodium dalconate were dissolved.
- a solution obtained by mixing and dissolving edible fats and emulsifiers at 70 to 80 ° C. was added thereto.
- the milk protein source material (Fontera: casein content: 66.8% by mass), sodium glutamate, mineral yeast mix, and flavor were added and mixed in this order to obtain a uniform dissolved and dispersed state.
- Aluminum criticisms were filled so that the mass per piece was 150g, and retort sterilization was performed by two-stage heat sterilization at 110 ° C and 126 ° C.
- This sample was stored at 25 ° C, and the day after sterilization was measured with a rotary viscometer (BH-80 (trade name), manufactured by Toki Sangyo) under the conditions of rotor No. 3 and 12 rpm. 2000 mPa's (25 ° C). The median diameter was measured using LS 13 320 (trade name, manufactured by Beckman Coulter, Inc.).
- the preparation method when 4000g is charged is described below.
- the amount of each raw material is as shown in Table 4. 1600g of prepared water was weighed in a 5L stainless steel bucket and heated to 70-80 ° C in a hot water bath. Next, with TK Robomix (registered trademark, manufactured by Tokushu Kika Kogyo Co., Ltd.), high-speed stirring conditions at 2000 rpm, dextrin, granulated sugar, water-soluble dietary fiber, ferrous citrate sodium, darconic acid Zinc, copper dalconate, sodium phosphate, sodium metaphosphate, potassium phosphate, tripotassium citrate, sodium dalconate and sodium chloride were dissolved.
- TK Robomix registered trademark, manufactured by Tokushu Kika Kogyo Co., Ltd.
- the preparation method when 4000g is charged is described below.
- the amount of each raw material is as shown in Table 5.
- 1630 g of prepared water was weighed in a 5 L stainless steel bucket and heated to about 85 ° C in a hot water bath. Next, powder agar was added to this and dissolved.
- TK Robotics registered trademark, manufactured by Tokushu Kika Kogyo Co., Ltd. It was dissolved in the order of dietary fiber, ferrous sodium citrate, zinc dalconate, copper dalconate, sodium phosphate, potassium phosphate, tripotassium citrate, sodium dalconate, and sodium chloride.
- Emulsifier 18,6 S [0051] (Example 4)
- Prototypes 1-5 were prepared as shown in Tables 6-8.
- the preparation method when 1500kg is charged is described below. After adding 500 kg (80-90 ° C) of preparation water to the preparation tank (hereinafter referred to as A), and then dissolving dextrin and granulated sugar using a powder dissolver, ferrous sodium citrate, phosphoric acid Potassium, tripotassium citrate, sodium dalconate, and lithium chloride were dissolved. Next, a liquid obtained by mixing and dissolving edible fats and oils, vitamin E-containing fats and fats and emulsifiers at 70 to 80 ° C was added from a powder dissolver.
- milk protein source material (Fontera, casein content 64.8%), sodium glutamate, cocoa powder, mineral yeast mix, and fragrance are charged from a powder dissolver, dissolved, mixed, and uniformly dissolved and dispersed. Held until.
- sodium ascorbate, sodium erythorbate and vitamin mix dissolved in the prepared water were added from a powder dissolver and dispersed and dissolved. After quantifying this liquid to 1500 kg, it was mixed and stirred until it became uniform.
- this solution is filled in a side gusseted aluminum bouch with a stopper (width 80mm x height 150mm x thickness 25mm) by a continuous filling machine via a liquid feed line, and one stage at 126 ° C.
- the retort process by the heat sterilization method was performed.
- This sample was stored at 25 ° C and sterilized.
- the feed rates of lactate, citrate magnesium and magnesium sulfate were varied so that the final viscosity was different.
- preparing Prototype 5 a step of dissolving and dispersing the thickener was added before the determination by the load cell in Test Example 4 below. Table 9 below shows the results of measuring the median diameter of the obtained prototypes 1 to 5 using LS 13 320 (trade name, manufactured by Beckman Coulter, Inc.).
- Prototype 6 having the composition shown in Tables 10 to 12 was prepared.
- the adjustment method when 1500kg is charged is described below.
- a solution obtained by mixing and dissolving edible fats and oils and an emulsifier at 70 to 80 ° C. was charged from a powder dissolver.
- milk protein source (Fontera A zein content of 64.8%), sodium glutamate, mineral yeast mix, and fragrance were added from a powder dissolver, dissolved, mixed, and held until a uniform dissolved and dispersed state was obtained.
- water-soluble dietary fiber, calcium lactate, magnesium chloride, and magnesium sulfate dissolved in the prepared water were gradually added from the powder dissolver.
- sodium ascorbate, sodium erythorbate and vitamin mix dissolved in the prepared water were added from a powder dissolver and dispersed and dissolved. The solution was mixed and stirred to 1500 kg until it became uniform.
- this solution was filled in a side gusseted aluminum bouch with a stopper (width 80 mm x height 150 mm x thickness 25 mm) through a liquid feed line and filled with 150 g (setting range 147 to 155 g). In the filling process, continuous filling was possible without any manufacturing problems. Thereafter, retort treatment was performed by a two-stage heat sterilization method at 115 ° C and 126 ° C. This sample was used as a sample for a long-term stability test.
- the tube fluidity of the nutritional composition of Example 1 was evaluated. Prepare a sample filled with 150 g in a standing aluminum bouch with a stopper (width 97 mm x height 138 mm x bottom folding diameter 25 mm), and connect a CPPEG connector (trade name, Hanaco Medical) to it. A gastrostomy feeding tube (Bird, supplied with the Bird Wizard) was connected. The tube part was 13cm long. Place a 5 kg weight (Sartorius, 87 mm diameter) on this sample and support it with your hand so that the weight does not fall on the sample. The contents were extruded with pressure for 1 minute 30 seconds. The mass of the extruded contents was measured.
- Example 1 had a large flow rate and excellent tube cleanability, but commercially available Telmir Soft and Telmir Soft M (registered trademark, made of Terumone Earth) did not have a flow rate, and the tube cleanability was also bad. I got it.
- the nutritional composition of Example 1 was subjected to particle size measurement and water insoluble matter analysis.
- the nutrient composition was diluted with an equal mass of water, collected in a 50 ml centrifuge tube, and centrifuged at 3, OOOrpm for 10 minutes with a centrifuge (H-103NR (trade name), manufactured by Kokusan).
- the precipitate was collected and redispersed with 40 ml of purified water, and then centrifuged again under the same conditions as described above.
- the precipitates separated into two layers (the upper layer precipitate was set as precipitate A and the lower layer precipitate was set as precipitate B) were collected, and the particle size, protein content, calcium content, and magnesium content were measured.
- the results of measuring the particle diameter are shown in Table 14, and the results of measuring each content are shown in Table 15. It can be seen that the nutritional composition of Example 1 has a mass of 1S 1.5 to 3 g / mmol of the total moles of calcium and magnesium.
- Example 1 Water or a thickener (carboxymethylcellulose: CMC) so as to show viscosity values (20, 200, 330, 1, 000, 2,000, 20, OOOmPa ⁇ s) in six stages, respectively. ) was added as appropriate, and phenol red dye (0.05% by mass) was further added to prepare each test solution.
- CMC carboxymethylcellulose
- gastrostomy and pyloric ligation were performed on 8-week-old SD male rats (215-265g) under Nembutal anesthesia. Immediately after ligation, each test solution was administered from the gastric fistula (2.5 ml Z rat). Ten minutes after administration, the gastric cardia was ligated, and the stomach and esophagus were removed without separation. The excised esophagus is incised, sprayed with NaOH, the length of the gastric cardia force in the colored (red) part of the reactive phenol red pigment is measured, and evaluated by the effect of each test solution on gastroesophageal reflux did.
- a CPPEG connector (trade name, Hanako Medical) was connected to the side plug of the side gusset aluminum bouch filled with each prototype, and a gastrostomy feeding tube (attached to Bird and Bird Wizard) was connected to the end.
- the tube part was 13cm long.
- a 5 kg weight (Sartorius, 87 mm in diameter) was gently placed at room temperature, and the sample was discharged for 40 seconds with a hand attached so that the weight did not fall off and was not over-pressurized. Thereafter, the mass of the discharged contents was measured.
- Each prototype was measured three times and the average value was determined.
- the viscosity when the discharge amount is 35.4 g is obtained from the graph force, it becomes 7,688 mPa's, and if it is at least 7, OOOmPa's, the composition having a practically preferable fluidity can be obtained. I think it can be done. In addition, as shown in the results of prototypes 1 to 3, it is clear that if the viscosity is 3, OOOmPa's or less, it exhibits excellent fluidity and can be used very easily.
- the prototype 6 obtained in Example 5 was subjected to a long-term stability test for up to 6 months when stored at room temperature (around 25 ° C).
- the physical properties of prototype 6 were measured at the start of the test and when allowed to stand for 1, 2, 4, and 6 months at room temperature (around 25 ° C).
- the refractive index is liquid (suspension part): 1 32, Sample: Real part 1.45, Imaginary part 0.
- a rotary viscometer (BH-80 (trade name), manufactured by Toki Sangyo Co., Ltd.), rotor No. 3 was used, and measurement was performed under the condition of 12 rpm.
- Table 17 shows the measurement results obtained. No significant changes were observed in the particle size distribution, viscosity, pH, and color difference after storage for 6 months, and all test items were within the specified range. That is, as a result of the long-term stability test, Prototype 6 was shown to be excellent in stability and retain sufficient stability as a product for at least 6 months.
- prototype 6 was further evaluated by conducting an accelerated test.
- the prototype 6 was allowed to stand at 40 ° C., and the physical properties of the prototype 6 after 1 and 2 months were measured by the above method at the start of the acceleration test.
- Viscosity (25 ° C) mPa ⁇ s 2760 2970 2865
- Table 18 shows the obtained results. As a result of the accelerated test, no significant changes were observed in the particle size distribution, viscosity, ⁇ , and color difference for 2 months from the start of the test, and all the test items were within the specified range. It was. In other words, prototype 6 was found to be excellent in stability even in the results of the accelerated test, and to maintain stability even when placed in a high-temperature environment in the short term.
- the prototypes 1, 3, and 4 were used as samples, and termir soft, termir soft M, and termir PG soft (registered trademark, manufactured by Termonet) were used as control samples, and a detergency test was performed under the following conditions. .
- the mass was measured in advance, and a balloon-type tube-type gastrostomy catheter (microbasic balloon G tube (trade name) manufactured by Boston 'Scientific' Japan, 24 Fr. (thickness)) with a CPPEG connector (Connect the CPPEG connector (trade name, Hanako Medical) to the balloon-type button type gastrostomy catheter (Bird Wizard (trade name), Bardone, 24Fr.)
- a 13 cm long gastrostomy feeding tube (attached to Bird, Bird Wizard) was connected to the tip. After about 10 g of each sample or control sample was passed through, 15 ml of water was injected from the drug solution port part of the catheter using a syringe and washed.
- Table 19 and Fig. 4 show the average value of the residual liquid amount in the tube type gastrostomy catheter
- Table 20 and Fig. 5 show the average value of the residual liquid amount in the button type gastrostomy catheter.
- the present invention is a high-protein nutritional composition that contains necessary nutrients other than protein without excess and deficiency, and can be easily and easily introduced into patients by various administration methods. Moreover, it is possible to provide a nutritional composition that is excellent in sterilization heat resistance and storage stability, and that can be mass-produced at low cost without requiring a complicated manufacturing apparatus process. In particular, even when the amount of protein or mineral is increased, it is possible to provide a nutritional composition having rheological properties that are favorable for oral intake and administration of tube force. More specifically, for example, a high-calorie nutritional composition exceeding 1.5 kcal Zml contains a sufficient amount of protein and minerals that were insufficient in conventional amounts when assuming energy intake of 1, OOOkcal / day. In addition, it is possible to provide a nutritional composition having no problem in manufacturing, distribution and use. Such a nutritional composition of the present invention can be used in the field of medical food industry.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Polymers & Plastics (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Pediatric Medicine (AREA)
- Mycology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0615126-4A BRPI0615126B1 (pt) | 2005-08-29 | 2006-07-18 | Composição nutriente |
EP06781205A EP1946764A4 (en) | 2005-08-29 | 2006-07-18 | NUTRIENT COMPOSITION |
AU2006286052A AU2006286052B2 (en) | 2005-08-29 | 2006-07-18 | Nutrient composition |
JP2007533132A JP5034946B2 (ja) | 2005-08-29 | 2006-07-18 | 栄養組成物 |
US12/038,290 US8652563B2 (en) | 2005-08-29 | 2008-02-27 | Nutrient composition |
US13/869,120 US8747939B2 (en) | 2005-08-29 | 2013-04-24 | Nutrient composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-248187 | 2005-08-29 | ||
JP2005248187 | 2005-08-29 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/038,290 Continuation US8652563B2 (en) | 2005-08-29 | 2008-02-27 | Nutrient composition |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007026474A1 true WO2007026474A1 (ja) | 2007-03-08 |
Family
ID=37808577
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/314192 WO2007026474A1 (ja) | 2005-08-29 | 2006-07-18 | 栄養組成物 |
Country Status (8)
Country | Link |
---|---|
US (2) | US8652563B2 (ja) |
EP (2) | EP1946764A4 (ja) |
JP (1) | JP5034946B2 (ja) |
KR (1) | KR101067266B1 (ja) |
CN (3) | CN102755634A (ja) |
AU (1) | AU2006286052B2 (ja) |
RU (1) | RU2390272C2 (ja) |
WO (1) | WO2007026474A1 (ja) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008301723A (ja) * | 2007-06-05 | 2008-12-18 | Nof Corp | 乳化状総合栄養食 |
JP2010120906A (ja) * | 2008-11-21 | 2010-06-03 | Ajinomoto Co Inc | 液状乳化栄養組成物 |
CN101854815A (zh) * | 2007-09-07 | 2010-10-06 | 富士胶片株式会社 | 粉末组合物 |
JP2011004702A (ja) * | 2009-06-29 | 2011-01-13 | Asahi Kasei Pharma Kk | 食物繊維含有栄養組成物 |
WO2012161253A1 (ja) | 2011-05-26 | 2012-11-29 | 株式会社カネカ | 水中油滴型乳化食品組成物の製造方法及び水中油滴型乳化食品組成物用添加剤 |
WO2014089526A1 (en) * | 2012-12-06 | 2014-06-12 | Bio Health Solutions, Llc | Treatment for chronic kidney disease |
JP2015091808A (ja) * | 2009-10-26 | 2015-05-14 | ネステク ソシエテ アノニム | 安定な増粘剤配合物 |
JP6012917B1 (ja) * | 2015-04-22 | 2016-10-25 | 日清オイリオグループ株式会社 | ゲル状組成物及びその製造方法 |
US9669010B2 (en) | 2012-12-06 | 2017-06-06 | Bio Health Solutions, Llc | Treatment for chronic kidney disease |
WO2018179953A1 (ja) * | 2017-03-30 | 2018-10-04 | テルモ株式会社 | 高カロリー栄養組成物および包装体 |
WO2018179952A1 (ja) * | 2017-03-30 | 2018-10-04 | テルモ株式会社 | 高カロリー栄養組成物および包装体 |
WO2018179955A1 (ja) * | 2017-03-30 | 2018-10-04 | テルモ株式会社 | 包装体 |
WO2018179954A1 (ja) * | 2017-03-30 | 2018-10-04 | テルモ株式会社 | 高カロリー栄養組成物および包装体 |
JP2020503002A (ja) * | 2017-01-11 | 2020-01-30 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 乳清タンパク質ミセルを含む乳清タンパク質とカゼイン供給源とによる、熱滅菌した高タンパク質でスプーン切れのよい栄養組成物 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011074670A1 (ja) * | 2009-12-18 | 2011-06-23 | 株式会社カネカ | 液状食品組成物 |
WO2012166743A2 (en) * | 2011-05-27 | 2012-12-06 | Tetragenetics, Inc. | Fusion proteins of ciliate granule lattice proteins, granular protein particles thereof, and uses therefor |
JPWO2014061808A1 (ja) * | 2012-10-19 | 2016-09-05 | Eaファーマ株式会社 | 胃ろう栄養患者用栄養組成物 |
US20160242450A1 (en) * | 2014-07-29 | 2016-08-25 | Rey Magana | Functional-gel Compositions and Methods |
AU2017214365B2 (en) * | 2016-02-03 | 2023-08-03 | Fresenius Kabi Deutschland Gmbh | High caloric, high protein nutritional formula comprising collagen |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01243970A (ja) * | 1988-03-18 | 1989-09-28 | Nippon Oil & Fats Co Ltd | 人工濃厚流動食 |
JPH0898647A (ja) * | 1994-09-30 | 1996-04-16 | Snow Brand Milk Prod Co Ltd | 金属結合カゼインを配合した栄養組成物 |
JP2000000077A (ja) * | 1997-11-07 | 2000-01-07 | Kyowa Hakko Kogyo Co Ltd | 蛋白質含有酸性飲食品 |
JP2001061444A (ja) * | 1999-08-25 | 2001-03-13 | Ajinomoto Co Inc | 高カロリー高蛋白質流動食 |
JP2002119246A (ja) * | 2000-10-17 | 2002-04-23 | Nisshin Pharma Inc | 経腸栄養組成物 |
JP2002142720A (ja) * | 2000-11-08 | 2002-05-21 | Otsuka Pharmaceut Factory Inc | 栄養組成物 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4213896A (en) * | 1979-04-26 | 1980-07-22 | Kraft, Inc. | Rennet casein and method for treatment thereof |
JPS5799158A (en) | 1980-12-11 | 1982-06-19 | Ajinomoto Co Inc | Production of soybean protein material |
US4695463A (en) * | 1985-05-24 | 1987-09-22 | Warner-Lambert Company | Delivery system for active ingredients and preparation thereof |
JPH01199565A (ja) | 1987-10-27 | 1989-08-10 | Terumo Corp | 水不溶性タンパク質を含有する飲料およびその製法 |
US5006559A (en) * | 1988-08-31 | 1991-04-09 | Clintec Nutrition Co. | Method of use of branched-chain amino acids infusions to influence appetite |
US5108767A (en) * | 1991-06-10 | 1992-04-28 | Abbott Laboratories | Liquid nutritional product for persons receiving renal dialysis |
JP2870304B2 (ja) | 1992-06-05 | 1999-03-17 | 不二製油株式会社 | 大豆蛋白粉末の製造法 |
US5488038A (en) * | 1992-11-27 | 1996-01-30 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Dibekacin derivatives and arbekacin derivatives active against resistant bacteria |
US5514655A (en) * | 1993-05-28 | 1996-05-07 | Abbott Laboratories | Enteral nutritional with protein system containing soy protein hydrolysate and intact protein |
US5514656A (en) * | 1993-05-28 | 1996-05-07 | Abbott Laboratories | Method of providing enteral nutritional support for patients undergoing radiation therapy and/or chemotherapy |
NZ260933A (en) | 1993-07-16 | 1996-07-26 | Hercules Inc | Cation-complexed polysaccharides; use in foods and pharmaceuticals |
US5635199A (en) * | 1995-10-27 | 1997-06-03 | Nestec Ltd. | Support of pediatric patients |
JPH119222A (ja) | 1997-06-20 | 1999-01-19 | Q P Corp | 嘔吐予防食品 |
CA2252691C (en) * | 1997-11-07 | 2005-12-06 | Kyowa Hakko Kogyo Co., Ltd. | Protein-containing acidic foods and drinks |
CO4970787A1 (es) * | 1997-12-23 | 2000-11-07 | Lilly Co Eli | Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea |
TW408153B (en) * | 1998-01-09 | 2000-10-11 | Asahi Chemical Ind | Cellulose-containing composite, process for its preparation and use thereof |
JP3312618B2 (ja) | 2000-02-03 | 2002-08-12 | 千住金属工業株式会社 | はんだ槽へのはんだの追加供給方法 |
NL1014380C2 (nl) * | 2000-02-14 | 2001-08-15 | Friesland Brands Bv | Darmwandversterkend voedingsmiddel. |
US20030130217A1 (en) * | 2000-02-23 | 2003-07-10 | Eyal Raz | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
GB0009056D0 (en) * | 2000-04-12 | 2000-05-31 | Nestle Sa | Composition comprising free amino acids |
JP2002172720A (ja) * | 2000-12-07 | 2002-06-18 | Takashimaya Nippatsu Kogyo Co Ltd | 内装基材 |
NZ511003A (en) | 2001-04-06 | 2003-06-30 | Fonterra Tech Ltd | preparing a fat containing stable dairy based food product such as cheese |
EP1553843B1 (en) * | 2001-05-31 | 2007-05-16 | New Zealand Dairy Board | Monovalent salt enhances solubility of milk protein concentrate |
US6605310B2 (en) * | 2001-06-06 | 2003-08-12 | Nestec S.A. | Calorically dense liquid oral supplement |
WO2003035112A1 (fr) * | 2001-10-22 | 2003-05-01 | Jiro Kanie | Nutriant enteral et procede de production de celui-ci |
JP4396815B2 (ja) | 2001-10-22 | 2010-01-13 | 治郎 蟹江 | 経腸栄養剤およびその製造方法 |
JP4063022B2 (ja) | 2002-09-11 | 2008-03-19 | 日油株式会社 | 液状飲食品用組成物および飲食品 |
JP2006109723A (ja) | 2004-10-13 | 2006-04-27 | Meiji Milk Prod Co Ltd | 易嚥下液状組成物 |
JP4972308B2 (ja) | 2004-12-02 | 2012-07-11 | 株式会社大塚製薬工場 | ゲル化栄養剤およびその製造方法 |
-
2006
- 2006-07-18 KR KR1020087004915A patent/KR101067266B1/ko active IP Right Grant
- 2006-07-18 WO PCT/JP2006/314192 patent/WO2007026474A1/ja active Application Filing
- 2006-07-18 CN CN2012102462345A patent/CN102755634A/zh active Pending
- 2006-07-18 CN CN201410181640.7A patent/CN103977392A/zh active Pending
- 2006-07-18 EP EP06781205A patent/EP1946764A4/en not_active Withdrawn
- 2006-07-18 EP EP13158625.7A patent/EP2668957A1/en not_active Withdrawn
- 2006-07-18 RU RU2008107750/13A patent/RU2390272C2/ru active
- 2006-07-18 JP JP2007533132A patent/JP5034946B2/ja active Active
- 2006-07-18 AU AU2006286052A patent/AU2006286052B2/en active Active
- 2006-07-18 CN CNA2006800313993A patent/CN101252947A/zh active Pending
-
2008
- 2008-02-27 US US12/038,290 patent/US8652563B2/en active Active
-
2013
- 2013-04-24 US US13/869,120 patent/US8747939B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01243970A (ja) * | 1988-03-18 | 1989-09-28 | Nippon Oil & Fats Co Ltd | 人工濃厚流動食 |
JPH0898647A (ja) * | 1994-09-30 | 1996-04-16 | Snow Brand Milk Prod Co Ltd | 金属結合カゼインを配合した栄養組成物 |
JP2000000077A (ja) * | 1997-11-07 | 2000-01-07 | Kyowa Hakko Kogyo Co Ltd | 蛋白質含有酸性飲食品 |
JP2001061444A (ja) * | 1999-08-25 | 2001-03-13 | Ajinomoto Co Inc | 高カロリー高蛋白質流動食 |
JP2002119246A (ja) * | 2000-10-17 | 2002-04-23 | Nisshin Pharma Inc | 経腸栄養組成物 |
JP2002142720A (ja) * | 2000-11-08 | 2002-05-21 | Otsuka Pharmaceut Factory Inc | 栄養組成物 |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008301723A (ja) * | 2007-06-05 | 2008-12-18 | Nof Corp | 乳化状総合栄養食 |
CN101854815A (zh) * | 2007-09-07 | 2010-10-06 | 富士胶片株式会社 | 粉末组合物 |
US8512758B2 (en) | 2007-09-07 | 2013-08-20 | Fujifilm Corporation | Powder composition |
JP2010120906A (ja) * | 2008-11-21 | 2010-06-03 | Ajinomoto Co Inc | 液状乳化栄養組成物 |
JP2011004702A (ja) * | 2009-06-29 | 2011-01-13 | Asahi Kasei Pharma Kk | 食物繊維含有栄養組成物 |
JP2015091808A (ja) * | 2009-10-26 | 2015-05-14 | ネステク ソシエテ アノニム | 安定な増粘剤配合物 |
WO2012161253A1 (ja) | 2011-05-26 | 2012-11-29 | 株式会社カネカ | 水中油滴型乳化食品組成物の製造方法及び水中油滴型乳化食品組成物用添加剤 |
EP3378324A1 (en) | 2011-05-26 | 2018-09-26 | Kaneka Corporation | Method for producing oil-in-water emulsified food product composition |
US9669010B2 (en) | 2012-12-06 | 2017-06-06 | Bio Health Solutions, Llc | Treatment for chronic kidney disease |
WO2014089526A1 (en) * | 2012-12-06 | 2014-06-12 | Bio Health Solutions, Llc | Treatment for chronic kidney disease |
WO2016170939A1 (ja) * | 2015-04-22 | 2016-10-27 | 日清オイリオグループ株式会社 | ゲル状組成物及びその製造方法 |
JP6012917B1 (ja) * | 2015-04-22 | 2016-10-25 | 日清オイリオグループ株式会社 | ゲル状組成物及びその製造方法 |
US11957147B2 (en) | 2017-01-11 | 2024-04-16 | Societe Des Produits Nestle S.A. | Heat sterilized high protein spoonable nutritional compositions with whey protein which comprises whey protein micelles and a source of casein |
JP2020503002A (ja) * | 2017-01-11 | 2020-01-30 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 乳清タンパク質ミセルを含む乳清タンパク質とカゼイン供給源とによる、熱滅菌した高タンパク質でスプーン切れのよい栄養組成物 |
WO2018179954A1 (ja) * | 2017-03-30 | 2018-10-04 | テルモ株式会社 | 高カロリー栄養組成物および包装体 |
WO2018179955A1 (ja) * | 2017-03-30 | 2018-10-04 | テルモ株式会社 | 包装体 |
WO2018179952A1 (ja) * | 2017-03-30 | 2018-10-04 | テルモ株式会社 | 高カロリー栄養組成物および包装体 |
JPWO2018179952A1 (ja) * | 2017-03-30 | 2020-02-06 | テルモ株式会社 | 高カロリー栄養組成物および包装体 |
JPWO2018179954A1 (ja) * | 2017-03-30 | 2020-02-06 | テルモ株式会社 | 高カロリー栄養組成物および包装体 |
JPWO2018179955A1 (ja) * | 2017-03-30 | 2020-02-06 | テルモ株式会社 | 包装体 |
JPWO2018179953A1 (ja) * | 2017-03-30 | 2020-02-06 | テルモ株式会社 | 高カロリー栄養組成物および包装体 |
JP7116043B2 (ja) | 2017-03-30 | 2022-08-09 | テルモ株式会社 | 高カロリー栄養組成物および包装体 |
WO2018179953A1 (ja) * | 2017-03-30 | 2018-10-04 | テルモ株式会社 | 高カロリー栄養組成物および包装体 |
Also Published As
Publication number | Publication date |
---|---|
US8652563B2 (en) | 2014-02-18 |
AU2006286052B2 (en) | 2011-02-03 |
RU2390272C2 (ru) | 2010-05-27 |
CN102755634A (zh) | 2012-10-31 |
CN101252947A (zh) | 2008-08-27 |
AU2006286052A1 (en) | 2007-03-08 |
KR101067266B1 (ko) | 2011-09-23 |
CN103977392A (zh) | 2014-08-13 |
EP2668957A1 (en) | 2013-12-04 |
JP5034946B2 (ja) | 2012-09-26 |
BRPI0615126A2 (pt) | 2013-01-01 |
EP1946764A1 (en) | 2008-07-23 |
JPWO2007026474A1 (ja) | 2009-03-05 |
US20080160137A1 (en) | 2008-07-03 |
EP1946764A4 (en) | 2009-08-26 |
KR20080038376A (ko) | 2008-05-06 |
US8747939B2 (en) | 2014-06-10 |
US20130243933A1 (en) | 2013-09-19 |
RU2008107750A (ru) | 2009-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5034946B2 (ja) | 栄養組成物 | |
EP2514321B1 (en) | Liquid food composition | |
JP6277957B2 (ja) | 栄養組成物 | |
JP5900347B2 (ja) | 乳化食品組成物 | |
TWI434659B (zh) | 包含碳水界面活性劑複合物之增黏營養乳劑 | |
CN106470561B (zh) | 稀释型营养组合物 | |
JP6408984B2 (ja) | 液状食品組成物の製造方法 | |
JP2007077107A (ja) | 液体栄養食品用ゲル化食品 | |
BRPI0615126B1 (pt) | Composição nutriente | |
JP2012144531A (ja) | 経腸栄養組成物 | |
JP2020200046A (ja) | 包装体 | |
JP2014108053A (ja) | 粘稠乳化状栄養食品およびその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680031399.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006286052 Country of ref document: AU |
|
REEP | Request for entry into the european phase |
Ref document number: 2006781205 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006781205 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2007533132 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008107750 Country of ref document: RU Ref document number: 1020087004915 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200800512 Country of ref document: VN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2006286052 Country of ref document: AU Date of ref document: 20060718 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0615126 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080225 |